Which factors influence the success of classical triple therapy in Helicobacter pylori eradication?;DE QUE FACTORES DEPENDE EL EXITO DE LA TRIPLE TERAPIA 'CLASICA' EN LA ERRADICACION DE HELICOBACTER PYLORI?

Revista Espanola de Enfermedades Digestivas

Volumn 88, Issue 5, 1996, Pages 317-322

  Gisbert, J P ^a,b,e   Boixeda, D ^a,b   De Rafael, L ^a,c   Redondo, C ^a,d   Martin de Argila C ^a,b   Bermejo, F ^a,b  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b Servicio de Gastroenterología   (Spain)

^c Servicio de Microbiología   (Spain)

^d Serv de Anat Patológica

^e C/ Lagasca 27 1oJ   (Spain)

Author keywords

duodenal ulcer; Helicobacter pylori; metronidazole

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; METRONIDAZOLE; OMEPRAZOLE; TETRACYCLINE; ANTACID AGENT; ANTIINFECTIVE AGENT; ANTIULCER AGENT; BISMUTH; PENICILLIN DERIVATIVE;

ADULT; ARTICLE; BACTERIAL INFECTION; BIOPSY; CLINICAL TRIAL; DRUG EFFICACY; DUODENUM ULCER; ENDOSCOPY; FEMALE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; COMPARATIVE STUDY; DRUG COMBINATION; HELICOBACTER INFECTION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; STATISTICAL MODEL; STOMACH; STOMACH ANTRUM;

ADULT; AMOXICILLIN; ANTACIDS; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BISMUTH; DRUG THERAPY, COMBINATION; DUODENAL ULCER; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LOGISTIC MODELS; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; PENICILLINS; PROSPECTIVE STUDIES; PYLORIC ANTRUM; STOMACH; TETRACYCLINE;

EID: 0030009095     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Marshall BJ y Warren JR. Unidentified curved bacilli in the stomach of patiens with gastritis and peptic ulceration. Lancet 1984; i: 1311-1314.
2. McNulty CAM y Watson DM. Spiral bacteria of the gastric antrum. Lancet 1984; i: 1068-1073.
3. Humphreys H, Bourke S, Dooley C, McKenna D, Power B, Keane CT et al. Effect of treatment on Campylobacter pylori in peptic disease a randomised prospective trial. Gut 1988; 29: 279-283.
4. Dooley CP y Cohen H. The clinical significance of Campylobacter pylon. Ann Intern Med 1988; 108: 70-79.
5. Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994; 89: S116-127.
6. a ed). St. Louis. Mosby 1994: 109-116.
7. Go MF y Graham DY. Helicobacter pylori gastroduodenal disease. En: Bayless TM. Current therapy in gastroenterology and liver diseases, fourth ed. St. Louis. Mosby 1994: 105-109.
8. NIH CONSENSUS CONFERENCE. Helicobacter pylon in peptic ulcer disease. JAMA 1994; 272: 65-69.
9. Wilde MI y McTavish D. Omeprazole: an update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994; 48: 91-132.
10. Labenz J, Gyenes E, Rühl GH y Börsch G. Efficacy of omeprazole and amoxicillin to eradicate Helicobacter pylori. Am J Gastroenterol 1992; 87: 1271.
11. Labenz J, Rühl GH, Bertrams J y Börsch G. Efficacy of medium and high-dose omeprazole plus amoxicillin for era-dication of Helicobacter pylori in gastric ulcer disease. Am J Gastroenterol 1993; 88: 1511.
12. Chiba N, Rao BV, Rademaker JW y Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992; 87:1716-1722.
13. Graham DY, Lew GM y Malty HM. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-496.
14. Cutler AF y Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol 1993; 88: 505-509.
15. Thijs JC, Van Zwett AA y Oey HB. Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori. Scand J Gastroenterol 1993; 28: 934-938.
16. Glupczynski Y, Burette A, de Koster E, Nyst JF, Deltenre M, Cadranel S et al. Metronidazole resistance in Helicobacter pylori. Lancet 1990; 335: 976-977.
17. Glupczynski y y Burette A. Drug therapy for Helicobacter pylori infection: problems and pitfalls. Am J Gastroenterol 1990; 85: 1545-1551.
18. Unge P y Ekström P. Effects of combination therapy with omeprazole and antibiotic on Helicobacter pylon and duodenal disease. Scand J Gastroenterol 1993; 28 (Suppl. 196): 17-18.
19. Atherton JC, Hudson N, Kirk GE, Hawkey CJ y Spiller RC. Should amoxycillin be taken before of after meals when prescribed with omeprazole for the eradication of Helicobacter pylori? A randomized controlled trial. Gastroenterology 1993; 104: A36.
20. Glupczynski Y. Metronidazole resistance in Helicobacter pylori: results of the second multicenter in vitro study. Fourth Workshop of the European Helicobacter study group. Ital J Gastroenterol 1991; 23 (suppl 2): A107.
21. Rautelin H, Seppälä K, Renkonen O, Vainio U y Kosunen TU. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother 1992; 36: 163-168.
22. López-Brea M, Sanz JC, Martín E, Moreno MJ y Alarcón T. In vitro susceptibility of Spanish clinical isolates of Helicobacter pylori to amoxicillin and metronidazole. Acta Gastroenterol Belg 1993; 56: 127.
23. Bell GD, Powell KU y Burridge SM. Experience with «triple» anti-Helicobacter pylori eradication therapy: side effects and importance of testing the pre-treatement bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 1992; 6: 427-431.
24. Weil J, Bell GD y Poxell DU. Helicobacter pylori infection treated with a tripotassium dicitrato bismuthate and metronidazole combination. Aliment Pharmacol Therap 1990; 4: 651-654.
25. Labenz J, Stolte M y Dominan C. Omeprazole plus amoxycillin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer disease. Am J Gastroenterol 1993; 88: 1511.
26. Labenz J, Gyenes E, Rühl y Börsch G. Omeprazole plus amoxycillin: efficacy of various treatment regimens to eradicate Helicobacter pylori. Am J Gastroenterol 1993; 4: 491-495.
27. Labenz J, Leverkus F y Börsch G. Omeprazole plus amoxycillin for cure of Helicobacter pylori infection. Factors influencing the treatment success. Scand J Gastroenterol 1994; 29: 1070-1075.
28. Archimandritis A, Balatsos V, Vassilios D, Mentis A, Kastanas K y Scandalis N. Triple therapy eradicated H. pylori equally in patients pretreated with omeprazole or ranitidine. A 12-month follow-up. J Clin Gastroenterol 1995; 20: 12-16.
29. Rauws EA, Langenberg W y Houthoff HJ. Campylobacter pyloridis-associated chronic active antral gastritis: A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988; 94: 33-40.
30. Valle J, Seppala K y Sipponen P. Disappearance of gastritis after eradication of Helicobaceter pylori: A morphometric study. Scand J Gastroenterol 1991; 26: 1057-1062.
31. Patchett S, Beattie S, Leen E, Keane C y O'Morain C. Helicobacter pylori and duodenal ulcer recurrence. Am J Gastroenterol 1992; 87: 24-27.
32. Borody TJ, Cole P y Noonan S. Long term Campylobacter pylori recurrence post eradication. Gastroenterology 1988; 94: A43.
33. Borody TJ, Brandl S, Andrews P, Ferch N, Jankiexicz E e Hyland L. Use of high efficay, lower dose triple threrapy to reduce side effects of eradicating Helicobacter pylori. Am J Gastroenterol 1994; 89: 33-37.
34. Truesdale RA, Chamberlain CE y Marin DF. Long-term follow-up and antibody response to tratement of patients with Helicobacter pylori. Gastroenterology 1990; 98: A140.
35. Burette A, Glupczinsky y y de Prez C. Evaluation of various multi-drug eradication regimens for Helicobacter pylori. Eur J Gastroenterol Hepatol 1992; 4: 817-820.